Science & Enterprise subscription

Follow us on Twitter

  • Researchers discovered a polymer compound added to insulin that in tests with pigs cuts insulin's acting time in ha… https://t.co/iHe65RlMnW
    about 55 mins ago
  • New post on Science and Enterprise: Polymer Boosts Insulin Speed, Stability https://t.co/PeSuWepIAH #Science #Business
    about 58 mins ago
  • A new venture investment company is funding start-ups at their earliest stages, with a goal of increasing support f… https://t.co/mM44gsVcT9
    about 1 day ago
  • New post on Science and Enterprise: Early Venture Investors Aim for Diverse Entrepreneurs https://t.co/y9tdzGJ9rP #Science #Business
    about 1 day ago
  • Fascinating hypothesis. We wrote about this team's work in nanomedicine for crossing blood-brain barrier in October… https://t.co/ud8TGIrXt7
    about 1 day ago

Please share Science & Enterprise

Mobile Heart Monitor Algorithm Approved in Europe

AliveECG app

AliveECG app on an Android device (AliveCor Inc.)

22 January 2015. An algorithm analyzing signals to detect atrial fibrillation from a heart monitor built into mobile devices received regulatory approval in Europe. AliveCor, a developer of heart monitoring systems for mobile devices, says the company received the Conformité Européene or CE mark for the algorithm that analyzes heart monitoring signals in its AliveECG App.

The CE Mark signifies approval to market regulated products such as medical devices in the European Union and associated countries, but the company says the AliveECG app is now available only in the U.K. and Ireland. The AliveECG app analyzes signals from AliveCor’s heart monitor app to detect atrial fibrillation. If the heart rhythm pattern suggests atrial fibrillation, the AliveECG app notifies the user. The data, stored online, can also be shared with physicians.

The AliveCor heart monitor works with Apple/iOS and Android mobile devices, and is intended for use by physicians for patients with known or suspected heart conditions, as well as health-conscious patients. In August 2014, the Food and Drug Administration approved the AliveECG algorithm for use in AliveCor systems sold in the U.S.

Atrial fibrillation, or AFib, is an irregular heartbeat that can lead to stroke or heart failure, and affects some 2 million people in the U.K. and Ireland, as well as 2.7 million Americans. With AFib, heart muscle contractions in the upper chambers beat irregularly instead of in a regular rhythm, which can cause blood to pool and lead to blood clots, including those that move to the brain and cause a stroke. Some 15 to 20 percent of stroke victims have this kind of irregular heartbeat, and left untreated, people with AFib are 4 to 5 times more likely to suffer a stroke.

While some people with AFib report symptoms, such as a racing heartbeat or light-headedness, many people with the condition experience no symptoms, making it difficult to detect. AliveCor, in San Francisco, says the AliveECG app reports the condition in real time for quick action by patients and physicians, which can be particularly important for people who do not experience symptoms.

Beginning in June 2014, AliveCor established heart monitoring centers at pharmacies in the U.K. and Ireland , where store customers could test for atrial fibrillation with the company’s heart monitor app. Community screenings of this kind are important, says the company, since about one-third of cases with AFib have not yet been diagnosed.

Read more:

*     *     *

Please share Science & Enterprise ...

1 comment to Mobile Heart Monitor Algorithm Approved in Europe